India's Biological E.

will produce the Johnson - Johnson (JNJ.N) COVID-19 vaccine along with its own candidate, its handling director told Reuters on Tuesday, which might increase the nation's total materials amidst a lack.

The infrastructure and plants are completely separate for both the items and we will be producing both independent of each other, Mahima Datla said in a text message, decreasing to provide any timeline or other details.

She informed Reuters in February that Biological E.

was seeking to contract-manufacture about 600 million dosages of the J-J vaccine every year.

India's federal government, however, did not consider any production of J-J this year in the nation in a list of likely vaccine output launched last week.J-J validated to Reuters it was dealing with Biological E.

on manufacturing its vaccine.

Our company believe Biological E.

will be a vital part of our global COVID-19 vaccine supply network, where multiple producing sites are associated with the production of our vaccine across various facilities, often in different countries and continents, before the vaccine can be distributed, a J-J India spokesperson said in an e-mail.

J-J said last month it had actually sought authorization to perform a local scientific trial in India for its single-dose vaccine.Biological E., based in the southern Indian city of Hyderabad, also plans to produce 75 million to 80 million dosages of its own vaccine a month from August.

The drug has actually been established with Baylor College of Medication in Houston and Dynavax Technologies Corp (DVAX.O).

The United States said in March it would finance Biological E.'s efforts to produce a minimum of 1 billion doses of COVID-19 vaccines by the end of 2022.

Reuters reported on Tuesday that India was unlikely to resume major exports of COVID-19 vaccines up until a minimum of October as it diverts shots for domestic use, a longer-than-expected delay set to get worse supply lacks from the international COVAX effort.